{"id":815466,"date":"2025-02-20T07:34:47","date_gmt":"2025-02-20T12:34:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/"},"modified":"2025-02-20T07:34:47","modified_gmt":"2025-02-20T12:34:47","slug":"altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/","title":{"rendered":"Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">GAITHERSBURG, Md., Feb.  20, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dKtXqWnOHMsNL9I5kj0h5A9WK_LDdgvnU327-R_zyLG_mTXNjvqtLVs-ZWXAL4jyAD8pmsdsJ49zoXBJR2xZUQ==\" rel=\"nofollow\" target=\"_blank\">Altimmune, Inc.<\/a> (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025.<\/p>\n<p align=\"justify\">Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune\u2019s Investor Relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G2Kv1EDX0h9DciJcC__VuNx32XEYVRA4PfaUhgWiuDDiACYnPG79o6avanJTaIwc0yC-RpcZ6mcXEYpcnmLmpLPaWMsC83kZpl2NEEHKIXit1GFIWlvpLHp3JXG7YaRz\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.altimmune.com\/investors<\/a>.<\/p>\n<p align=\"justify\">Participants who would like to join the call may register <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YoX9nwPnsAhKUwJ3meLaiTVC478ATYjTg7pkO6RcmnZ2pMJ6QBXI6jJLqeT87_tQeLk0Q5DBoBAaURhI7_YarpIalHb2U0jzVJ8JYSXfH0bU5yAlDlV0L-a2hMMZNBXLqRtHnBZs4FycIciK6A6ZSg==\" rel=\"nofollow\" target=\"_blank\">here<\/a> to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.<\/p>\n<p>\n        <strong>About Altimmune<\/strong>\n      <\/p>\n<p align=\"justify\">Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1\/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fp-7M2x6o-VWVr2DNQ0m33mhmYOAGTGadmH8EbOoeFQuRR1dgriSUm61Y9cT0ujqmV57hlWeFYk7nIbRSj-iUEFR73XDjssN4gaflvqGMe4=\" rel=\"nofollow\" target=\"_blank\">www.altimmune.com<\/a>.<\/p>\n<p>\n        <strong>Follow @Altimmune, Inc. on <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h3E_ARmBQ4IM8y2WSKTzz4jhUj1tAba7whPNJwDr5Jt_Gtdkvk9YQzYlx7BeXCByy_ekEGoRF790gj-KzmD8F_mwa_F5uS18Wo3F0KJP4Xc=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>LinkedIn<\/strong><br \/>\n        <\/a><br \/>\n        <br \/>\n        <strong>Follow @AltimmuneInc on <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J4u43bBfuHlwU3ZART1hDZMZjFutaImxYkgkgDAk0XjDGlm2cDzaMJiCORftxedso4KEwc3J6qpBAiB6oSk7ZA==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>Twitter<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>Greg Weaver<br \/>Chief Financial Officer<br \/>Phone: 240-654-1450<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AnXdH9DLsNmAnusS8qEhXBQTeqdOXeSPC9f4g7mdUum61iblDfqrhEJoYqelwPgdYV4LmMzDSoQvgpogXnrAvQ==\" rel=\"nofollow\" target=\"_blank\">ir@altimmune.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Lee Roth<br \/>Burns McClellan<br \/>Phone: 646-382-3403<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OvILoCMn9j67XTzoDHFUvFo8xeZRM1idiVW4zLxSt6915asmguRcc6n9U9lm19YOE79dx2ytZPlhIg8jCGCjKO3_KomSKwIhEFYKX2JHvJo=\" rel=\"nofollow\" target=\"_blank\">lroth@burnsmc.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Danielle Cantey<br \/>Inizio Evoke, Biotech<br \/>Phone: 619-826-4657<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ssYUVd15RZkiEWiwM4D5T2yEecCCAN7BAzOYq1yqDPAr7F0NsMbzWjOAddrXP8WlQ-uQCZyNAsscG0Zw4mjbo63Pgd620D9ZryOCnwo9wQP66cmtKdOqh0AQF_mTNUVd\" rel=\"nofollow\" target=\"_blank\">Danielle.cantey@inizioevoke.com<\/a><\/p>\n<p>This press release was published by a CLEAR\u00ae Verified individual.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTM5MCM2NzU5MzgxIzIwMTA2NzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWFkM2JkYjUtNjk5Mi00MjRhLTgzNzgtMjZhZmE3NzFjNjhmLTEwMjIyNDk=\/tiny\/Altimmune-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune\u2019s Investor Relations website at https:\/\/ir.altimmune.com\/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months. About Altimmune Altimmune is a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-815466","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune\u2019s Investor Relations website at https:\/\/ir.altimmune.com\/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months. About Altimmune Altimmune is a &hellip; Continue reading &quot;Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-20T12:34:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTM5MCM2NzU5MzgxIzIwMTA2NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025\",\"datePublished\":\"2025-02-20T12:34:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\\\/\"},\"wordCount\":223,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTM5MCM2NzU5MzgxIzIwMTA2NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\\\/\",\"name\":\"Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTM5MCM2NzU5MzgxIzIwMTA2NzY=\",\"datePublished\":\"2025-02-20T12:34:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTM5MCM2NzU5MzgxIzIwMTA2NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTM5MCM2NzU5MzgxIzIwMTA2NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/","og_locale":"en_US","og_type":"article","og_title":"Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 - Market Newsdesk","og_description":"GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune\u2019s Investor Relations website at https:\/\/ir.altimmune.com\/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months. About Altimmune Altimmune is a &hellip; Continue reading \"Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-20T12:34:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTM5MCM2NzU5MzgxIzIwMTA2NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025","datePublished":"2025-02-20T12:34:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/"},"wordCount":223,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTM5MCM2NzU5MzgxIzIwMTA2NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/","name":"Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTM5MCM2NzU5MzgxIzIwMTA2NzY=","datePublished":"2025-02-20T12:34:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTM5MCM2NzU5MzgxIzIwMTA2NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTM5MCM2NzU5MzgxIzIwMTA2NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-update-on-february-27-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815466","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=815466"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815466\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=815466"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=815466"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=815466"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}